Organon stock price surges 6%, no improper conduct found in audit

2026-02-20 13:26:43

Abstract generation in progress

Investing.com – Organon & Co. (NYSE: OGN) stock rose 6% on Friday morning after the company’s audit committee completed an independent review, finding no misconduct related to transactions involving the purchase of biosimilars from suppliers in previous years.

According to documents filed with the U.S. Securities and Exchange Commission, Organon’s board of directors’ audit committee completed the independent review with the assistance of outside counsel. The review concluded that no action was necessary.

The company stated that the independent review found no evidence of misconduct related to the relevant transactions. The review also did not identify any issues requiring adjustments to Organon’s previously issued financial statements or disclosures filed with the SEC.

The audit committee initiated this independent review after learning about the timing of the company’s biosimilar purchases from suppliers in previous years on February 11. The company disclosed the review on February 12.

Organon stated it will file its Form 10-K for the fiscal year ending December 31, 2025, on time.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.